Open an account

Invivyd

IVVD · NASDAQ

$0.6366+$0.0266 (+4.36%)TodayMarket closed ·
Prev close $0.61

About IVVD

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 122 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Employees
122
Headquarters
New Haven, Connecticut
Listed
Aug 6, 2021
Sector
Health Care
Industry
Biotechnology
Website
invivyd.com

IVVD key statistics

Market cap
187.64M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.33M
Volume
2.27M
Open price
$0.6217
High today
$0.6509
Low today
$0.617
52 Week high
$3.01
52 Week low
$0.5277

Invivyd (IVVD) at a glance

Invivyd (IVVD) last traded at $0.6366, with a market cap of 187.64M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.617 and $0.6509. The current price is 3.2% above the day's low and 2.2% below its high.

Volume so far is 2.27M shares, below the average of 7.33M shares a day.

Over the past year Invivyd has ranged from $0.5277 to $3.01, and now sits 4% of the way up that range.

Invivyd met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1088.

The average analyst price target is $10.20, 1502.3% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 5 analystsAvg $10.20
Low
$10.10
Now
$0.6366
High
$10.50

IVVD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 27.9% on average.

  1. Q3 FY24: reported -$0.51 per share against an estimate of -$0.3443
  2. Q4 FY24: reported -$0.20 per share against an estimate of -$0.204
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.0306
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.0238
  5. Q3 FY25: reported -$0.06 per share against an estimate of -$0.0816
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0893
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.0748
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1088

IVVD news

  • Press releaseGlobe Newswire

    Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

  • Vandana Singh

    Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript

  • Press releaseGlobe Newswire

    Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    Nasdaq Down 1%; Medtronic Earnings Top Views

Similar companies

Companies in the same industry as Invivyd

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.